Septerna Stock price
Compare with Peer Group
📊 Peer Group
📈 What is it?
The peer group consists of the companies with the most similar business model. They serve as a benchmark for putting a stock into context.
🧮 How is it selected?
Based on similarity of business model, meaning companies from the same industry with comparable products and a similar customer base. That's the only way to compare apples to apples.
🏛️ Why does it matter?
Whether a stock is cheap or expensive is best judged by comparison. A P/E of 18 or an EV/FCF of 20 can look cheap or expensive depending on the yardstick. The peer group gives you the most accurate one: companies with a similar business model that operate under the same conditions.
🎯 What does it mean for investors?
When a metric sits below the peer average, the stock is valued more cheaply relative to its competitors, and above the average more expensively. A discount to the peer group can be an opportunity, but it can also have a reason (for example lower growth). The comparison is a starting point, not a verdict.
Is Septerna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.
StocksGuide Premium
StocksGuide Unlimited
Key metrics
📘 Market Capitalization
📈 What is it?
Market capitalization shows how much a company is currently worth on the stock market.
🧮 How is it calculated?
🏛️ Why is it important?
It helps classify companies by size (Large, Mid, Small Cap) and indicates their market presence and relative stability.
🧮 Calculation
🎯 What does this mean for investors?
- Large-cap companies tend to be more stable, often pay dividends, but may grow more slowly.
- Smaller firms may offer higher growth potential but come with more volatility.
- Market capitalization is a useful indicator of company size — but not a measure of whether a stock is undervalued or overvalued.
📘 Enterprise Value (EV)
📈 What is it?
Enterprise Value represents the total cost to acquire a company — including its debt and excluding its cash reserves.
🧮 How is it calculated?
(= Market Cap + Net Debt)
🏛️ Why is it important?
EV gives a more complete picture of a company's value than market cap alone and is used in key valuation ratios like EV/FCF or EV/Sales.
🧮 Calculation
🎯 What does this mean for investors?
- Enterprise Value shows the true cost of buying a company, including all financial obligations.
- It is more accurate than just looking at market cap, especially when comparing companies with different levels of debt or cash.
- Professional investors prefer EV-based multiples because they better reflect the company’s full financial footprint.
📘 Net Debt
📈 What is it?
Net Debt shows how much debt remains after subtracting a company’s available cash reserves.
🧮 How is it calculated?
🏛️ Why is it important?
It indicates how dependent a company is on borrowed money and how easily it can service its debt in the short term.
🧮 Calculation
🎯 What does this mean for investors?
- Low or negative net debt signals financial strength and flexibility.
- Companies with strong cash positions are better positioned in crises.
- High net debt increases financial risk — especially in environments with rising interest rates or economic downturns.
📘 Cash
📈 What is it?
Cash represents all liquid assets a company can access immediately — including cash, bank deposits, and short-term investments.
🧮 How is it calculated?
🏛️ Why is it important?
It reflects a company’s financial flexibility and resilience — enabling investments, buybacks, or buffer in downturns.
🧮 Calculation
🎯 What does this mean for investors?
- A strong cash position means greater room for maneuver and crisis resistance.
- Cash-rich companies can invest, pay down debt, or repurchase shares.
- But excess idle cash might indicate a lack of growth opportunities.
📘 Shares Outstanding
📈 What is it?
Shares outstanding represent the total number of a company’s shares currently held by investors — excluding treasury stock.
🧮 How is it calculated?
🏛️ Why is it important?
It’s the basis for key metrics like Earnings Per Share (EPS), Market Capitalization, or the Price/Earnings ratio (P/E).
🧮 Calculation
🎯 What does this mean for investors?
- Fewer shares in circulation typically increase earnings per share — making each share more valuable.
- Share buybacks reduce the number of shares and boost per-share metrics.
- Issuing new shares does the opposite — diluting shareholder value and lowering per-share figures.
📘 Price-to-Earnings Ratio (P/E)
📈 What is it?
The P/E ratio shows how many times a company's earnings per share are reflected in its current share price — in other words, how "expensive" the stock appears relative to its profits.
🧮 How is it calculated?
🏛️ Why is it important?
The P/E ratio is one of the most widely used valuation metrics. It helps investors assess whether a stock appears cheap or expensive compared to its earnings power.
🧮 Calculation
📊 P/E (TTM) = Based on earnings from the last 12 months (Trailing Twelve Months):🎯 What does this mean for investors?
- A low P/E may indicate undervaluation — or signal underlying issues.
- A high P/E may reflect strong growth expectations — or an overvalued stock.
📘 Price-to-Sales Ratio (P/S)
📈 What is it?
The P/S ratio shows how much investors are paying for $1 of the company’s revenue – regardless of profitability.
🧮 How is it calculated?
🏛️ Why is it important?
P/S is especially useful for evaluating growth companies or businesses not yet profitable. It reflects how the market values the company’s sales.
🧮 Calculation
Market Cap = $1.88b | Revenue (TTM) = $98.88m
Market Cap = $1.88b | Estimated Revenue = $99.96m
🎯 What does this mean for investors?
- A low P/S may indicate undervaluation — or low profitability.
- A high P/S can reflect strong growth expectations — or excessive optimism.
- Especially helpful when evaluating companies where profits are low, volatile, or negative.
📘 Enterprise Value to Sales (EV/Sales)
📈 What is it?
EV/Sales shows how much investors are paying for $1 of revenue — considering not just equity, but also debt and cash. It’s the capital structure–adjusted version of the P/S ratio.
🧮 How is it calculated?
🏛️ Why is it important?
It’s ideal for comparing companies with different levels of debt. It reflects a company's true cost relative to its revenue.
🧮 Calculation
Enterprise Value = $1.50b | Revenue (TTM) = $98.88m
Enterprise Value = $1.50b | Forward Revenue = $99.96m
🎯 What does this mean for investors?
- EV/Sales allows for capital structure–neutral company comparisons.
- A lower ratio may indicate undervaluation; a higher one may signal strong growth expectations or overvaluation.
- Especially helpful when evaluating high-growth companies with low or negative earnings.
📘 Enterprise Value to Free Cash Flow (EV/FCF) | ex SBC
📈 What is it?
EV/FCF compares a company’s enterprise value with its free cash flow. The metric therefore shows the multiple of current free cash flow at which a company is valued. EV/FCF ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted version.
🧮 How is it calculated?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cash Flow (TTM) − SBC)
🏛️ Why is it important?
EV/FCF provides a valuation based on free cash flow and therefore complements earnings-based valuation metrics such as the P/E ratio. The ex SBC version additionally accounts for the economic impact of stock-based compensation and provides a more conservative view from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A low EV/FCF means that enterprise value is low relative to current free cash flow. The reasons should always be considered in the context of the company and its industry.
- A high EV/FCF means that enterprise value is high relative to current free cash flow. This can, for example, reflect high growth expectations or temporarily weak cash generation.
- When SBC is positive and adjusted free cash flow remains positive, EV/FCF ex SBC is generally higher than the standard EV/FCF.
- The metric is particularly useful for companies with relatively stable and predictable cash flows.
- If free cash flow is negative or very low, EV/FCF has limited usefulness and should not be interpreted like a standard valuation multiple.
📘 Price-to-Book Ratio (P/B)
📈 What is it?
The P/B ratio compares a company’s market value to its book value — showing how much investors are paying for each dollar of net assets.
🧮 How is it calculated?
🏛️ Why is it important?
P/B is commonly used for asset-heavy industries like banks or industrials. It helps assess whether a stock is trading above or below its net asset value.
🧮 Calculation
🎯 What does this mean for investors?
- A P/B below 1 may signal undervaluation — or weak profitability.
- A P/B above 1 implies the market expects future value creation (e.g., brand, IP, growth).
- Best used for companies with tangible assets and strong balance sheets.
📘 Equity Ratio
📈 What is it?
The equity ratio indicates what portion of a company’s total assets is financed by shareholders’ equity – in other words, how much it relies on its own capital.
🧮 How is it calculated?
🏛️ Why is it important?
A high equity ratio reflects financial strength and stability, especially during downturns. It’s a key indicator of a company’s solvency and long-term risk profile.
🧮 Calculation
🎯 What does this mean for investors?
- Companies with high equity ratios are generally more resilient and less dependent on external debt.
- Low equity ratios can signal higher risk or aggressive financial strategies.
- Important: Always assess the equity ratio in combination with the return on equity (ROE). This shows not just how stable the company is – but also how efficiently it uses shareholder capital.
📘 Return on Equity (ROE)
📈 What is it?
Return on equity (ROE) shows how efficiently a company uses its shareholders’ equity to generate profit. In other words: how much net income is earned per dollar of equity.
🧮 How is it calculated?
🏛️ Why is it important?
ROE is a core profitability metric. It helps investors understand whether a company delivers attractive returns on the capital provided by its shareholders.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROE indicates that the company is using its capital efficiently and profitably.
- It’s especially meaningful for capital-intensive businesses or firms with high equity bases.
- Important: A very high ROE can also result from high debt levels – always interpret it alongside the equity ratio to assess financial health.
📘 Return on Capital Employed (ROCE)
📈 What is it?
ROCE measures how efficiently a company generates profits from its total capital – including both equity and interest-bearing debt.
🧮 How is it calculated?
It evaluates the return on all capital employed, regardless of how it’s financed.
🏛️ Why is it important?
ROCE is ideal for comparing companies with different financing structures. It shows how well management uses capital to create value for both shareholders and creditors.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROCE means the company uses its capital efficiently – regardless of whether it's funded by debt or equity.
- The higher the ROCE compared to peers, the more value the company creates with its invested capital.
- Especially relevant for capital-intensive sectors like industrials, energy, or infrastructure.
📘 Return on Invested Capital (ROIC)
📈 What is it?
ROIC measures how efficiently a company generates returns from the capital invested in its core operations – regardless of whether the capital comes from equity or debt.
🧮 How is it calculated?
- NOPAT = Net Operating Profit After Taxes
- Invested Capital = Operating assets minus non-interest-bearing liabilities
🏛️ Why is it important?
ROIC is one of the most accurate indicators of capital efficiency. Unlike return on equity, it is not distorted by leverage and shows how much value is created for all capital providers.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROIC shows how effectively a company uses the capital that is truly invested in its core operations.
- Unlike ROCE, ROIC focuses only on the capital that is actively used to run the business – and that requires a return (i.e. interest-bearing).
- Especially useful when comparing companies with large amounts of excess cash or non-interest-bearing liabilities – giving a more realistic picture of capital efficiency.
📘 Leverage Ratio (Debt-to-Equity)
📈 What is it?
The leverage ratio indicates how much a company relies on interest-bearing debt (such as loans and bonds) relative to its shareholders’ equity.
🧮 How is it calculated?
🏛️ Why is it important?
This ratio helps assess a company’s financial structure and risk profile. High leverage can enhance returns – but also increases exposure to interest rate changes and financial stress.
🧮 Calculation
🎯 What does this mean for investors?
- A low leverage ratio signals financial strength and independence.
- A higher ratio can improve returns in good times but increases risk during downturns or rising interest rate periods.
- 👉 Always interpret in the context of industry, capital intensity, and interest rate environment.
📘 SBC | in % Revenue
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to revenue.
🧮 How is it calculated?
SBC as % of Revenue = (SBC ÷ Revenue) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of revenue shows how heavily a company relies on equity-based compensation and how significant this form of compensation is relative to the size of the business.
🧮 Calculation
🎯 What does this mean for investors?
- A lower figure is generally positive: Stock-based compensation is relatively small compared with the company's revenue.
- A high figure can indicate greater reliance on stock-based compensation and a higher potential risk of dilution. However, it is also important to consider whether the company offsets dilution through share buybacks.
- The trend over time should also be considered. A high but declining percentage presents a different picture from a persistently high or increasing percentage.
- A single-digit SBC-to-revenue ratio is not unusual among many growth-oriented and technology companies.
📘 SBC as % of FCF
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to free cash flow (FCF).
🧮 How is it calculated?
SBC as % of FCF = (SBC ÷ Free Cash Flow) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of free cash flow shows how significant SBC is relative to the cash generated by the company. Since SBC is non-cash compensation, it is typically not deducted as a cash outflow when calculating FCF.
🧮 Calculation
🎯 What does this mean for investors?
- A lower value is generally favorable. Stock-based compensation is relatively small compared with the company's cash generation.
- A high value means that SBC represents a significant portion of the company's reported free cash flow, even though SBC itself is non-cash.
- The higher the value, the more significant SBC can be as an economic cost to shareholders, particularly when it results in share dilution.
📘 SBC Growth 1Y
📈 What is it?
SBC Growth 1Y shows how much a company's stock-based compensation has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
SBC Growth shows whether stock-based compensation is becoming more or less significant for shareholders. If SBC increases significantly, it can lead to greater shareholder dilution over time. At the same time, SBC is a non-cash expense that reduces earnings on the income statement but is added back in the cash flow statement.
🧮 Calculation
🎯 What does this mean for investors?
- A high positive value is generally negative, as rising SBC can increase the burden on shareholders, particularly through potential dilution.
- What matters is whether the development of SBC is sustainable over the long term. Some level of SBC is common among many growth and technology companies.
📘 Share Count Growth 1Y
📈 What is it?
Share Count Growth 1Y shows how much the number of shares outstanding has increased or decreased over a one-year period.
🧮 How is it calculated?
🏛️ Why is it important?
The number of shares determines how many shares the company's earnings and assets are distributed across. If the share count decreases, existing shareholders' relative ownership increases. If it increases, existing shareholders are diluted. The metric therefore makes dilution and share buybacks directly visible.
🧮 Calculation
🎯 What does this mean for investors?
- A negative value is generally positive, as the number of shares outstanding is decreasing.
- A positive value indicates dilution of existing shareholders.
- A declining share count is not automatically positive: It also matters at what price the shares are repurchased and how the buybacks are financed.
📘 Shareholder Yield
📈 What is it?
Shareholder Yield measures how much capital a company returns to shareholders through dividends and share buybacks, relative to its market capitalization. It goes beyond dividend yield by also including share buybacks.
🧮 How is it calculated?
🏛️ Why is it important?
Dividend yield only tells part of the story. When a company buys back shares and the share count falls, each existing shareholder owns a larger part of the company. When the share count rises, for example through stock-based compensation or new share issuance, existing shareholders are diluted. Shareholder Yield combines both into one metric.
🧮 Calculation
🎯 What does this mean for investors?
- A higher Shareholder Yield indicates more capital being returned to shareholders.
- A negative value means the company issued more new shares than its dividends and buybacks make up for.
- Share buybacks are most beneficial when shares are repurchased at attractive valuations.
- Investors should also consider whether dividends and buybacks are sustainable over time.
📘 Revenue
📈 What is it?
Revenue shows how much a company earns in total from selling its products and services – the gross income before any costs are deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Revenue is one of the key figures to assess a company’s size, market position, and growth potential.
🧮 Calculation
🎯 What does this mean for investors?
- Growing revenue indicates rising demand and can be an early signal of future earnings growth.
- Comparing actual and expected revenue reveals trends in the market environment and analyst sentiment.
- Note: Strong revenue alone isn’t enough – margins and profitability matter just as much.
📘 EBITDA
📈 What is it?
EBITDA stands for “Earnings Before Interest, Taxes, Depreciation, and Amortization.” It reflects a company’s operating profit before the effects of financing, taxes, and accounting depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
EBITDA is widely used to evaluate a company’s operating performance – especially across capital-intensive sectors or international comparisons.
🧮 Calculation
🎯 What does this mean for investors?
- A high or growing EBITDA indicates strong operational profitability – independent of taxes, interest, or accounting methods.
- It’s especially useful for comparing companies across sectors or geographies.
- Important: EBITDA is not a net income figure – it excludes key costs like depreciation and interest.
📘 EBIT
📈 What is it?
EBIT stands for “Earnings Before Interest and Taxes.” It reflects a company’s operating profit after depreciation, but before interest and tax expenses.
🧮 How is it calculated?
🏛️ Why is it important?
EBIT is a core profitability metric that shows how well the company performs in its main business operations – independent of capital structure and tax environment.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT indicates strong profitability from the company’s core business – before financial and tax effects.
- It allows better comparison between companies with different debt levels or tax structures.
- Compared to EBITDA, EBIT already accounts for depreciation and reflects capital intensity more clearly.
📘 Net Income
📈 What is it?
Net income is the company’s total profit – the amount left after all expenses, taxes, interest, and depreciation have been deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Net income is the most comprehensive measure of a company’s profitability – showing how much actual profit remains after all business and financing costs.
🧮 Calculation
🎯 What does this mean for investors?
- Growing net income indicates that the company is managing all of its costs efficiently.
- It directly influences valuation metrics like P/E ratio and the company’s dividend capacity.
- Over time, net income trends reveal how resilient and profitable the business model really is.
📘 Free Cash Flow (FCF) | ex SBC
📈 What is it?
Free cash flow shows how much cash remains after a company has covered its operating and capital expenditures. FCF ex SBC additionally deducts stock-based compensation (SBC) to adjust the cash flow for the effect of non-cash SBC.
🧮 How is it calculated?
Free Cash Flow ex SBC = Operating Cash Flow − SBC − Capital Expenditures (CAPEX)
🏛️ Why is it important?
FCF reflects a company’s actual financial strength – independent of reported accounting earnings. It shows how much flexibility a company has for dividends, share buybacks, or debt reduction. FCF ex SBC also deducts stock-based compensation and shows how much cash generation remains after SBC.
🧮 Calculation
🎯 What does this mean for investors?
- High free cash flow indicates that a company has strong financial strength – independent of reported earnings.
- It is often a solid basis for sustainable dividends and share buybacks.
- Declining FCF can be a warning sign, even if reported earnings remain stable.
📘 Revenue Growth
📈 What is it?
Revenue growth shows how much a company’s sales have changed compared to the previous year – both on a trailing basis (TTM) and based on forward projections.
🧮 How is it calculated?
Forward = (Expected revenue ÷ Revenue in prior year − 1) × 100
Forward growth is based on analyst estimates for the current fiscal year.
🏛️ Why is it important?
Rising revenue signals growing demand, business expansion, and market share gains – especially important for growth-oriented companies.
🧮 Calculation
🎯 What does this mean for investors?
- Growth is the engine of long-term value creation – especially in tech and growth sectors.
- What matters is not just current growth, but its sustainability.
- Forward projections reflect whether analysts expect continued momentum – or a slowdown.
📘 EBITDA Growth
📈 What is it?
EBITDA growth shows how much a company’s operating profit (before interest, taxes, depreciation, and amortization) has increased or decreased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBITDA ÷ EBITDA from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
Growing EBITDA indicates improving operational profitability – regardless of financing or accounting effects.
🧮 Calculation
🎯 What does this mean for investors?
- Strong EBITDA growth signals operational efficiency and scalability – especially during growth phases.
- EBITDA growth can be an early indicator of margin and earnings expansion – but should be assessed alongside revenue and EBIT.
📘 EBIT Growth
📈 What is it?
EBIT growth shows how much a company’s operating profit (after depreciation, but before interest and taxes) has increased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBIT ÷ EBIT from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
EBIT growth is a direct indicator of a company’s business performance – taking into account capital intensity through depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- Rising EBIT signals improving operating profitability – even after accounting for depreciation.
- It’s especially important for evaluating companies with significant capital expenditures.
- Combined with revenue and EBITDA growth, EBIT growth provides a well-rounded view of operational progress.
📘 Net Income Growth
📈 What is it?
Net income growth shows how much a company’s bottom-line profit has increased or decreased compared to the previous year – both on a trailing basis (TTM) and based on analyst projections.
🧮 How is it calculated?
Forward = (Expected net income ÷ Net income from prior year − 1) × 100
The forward estimate reflects analysts’ expectations for the current fiscal year.
🏛️ Why is it important?
Net income is the ultimate measure of profitability. Growing net income signals stronger efficiency, cost control, and sustainable earnings power.
🧮 Calculation
🎯 What does this mean for investors?
- Stronger net income boosts valuation, dividend potential, and investor confidence.
- If profits stall while revenue grows, it may signal margin pressure.
📘 Free Cash Flow Growth
📈 What is it?
Free cash flow (FCF) growth shows how a company’s available cash – after covering operating expenses and capital expenditures – has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
Free cash flow reflects real financial strength. Growing FCF indicates more flexibility for dividends, share buybacks, and reinvestment.
🧮 Calculation
🎯 What does this mean for investors?
- Declining FCF may point to rising investments, increasing costs, or weaker operating performance.
- Especially for dividend investors, FCF growth is critical – since dividends are paid from actual available cash.
- A negative trend isn't always bad, but it deserves closer attention.
📘 Gross Margin
📈 What is it?
Gross margin shows how much of a company’s revenue remains after deducting the direct costs of goods sold (like materials and production). It represents the company’s “raw profit” before fixed costs, taxes, and interest.
🧮 How is it calculated?
Or simply: Gross Margin = Gross Profit ÷ Revenue × 100
🏛️ Why is it important?
Gross margin indicates how efficiently a company can produce or procure what it sells. It is a key measure of product-level profitability and pricing power.
🎯 What does this mean for investors?
- A high gross margin suggests strong pricing power and efficient production.
- Falling margins may signal rising input costs or competitive pressure.
- Compared to peers, gross margin offers insights into the quality of a business model.
📘 EBITDA Margin
📈 What is it?
The EBITDA margin shows how much of a company’s revenue remains as operating profit before interest, taxes, depreciation, and amortization.It reflects operating efficiency without being distorted by financing or accounting factors.
🧮 How is it calculated?
🏛️ Why is it important?
The EBITDA margin reveals how much operating income a company generates per dollar of revenue – independent of capital structure and tax effects.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBITDA margin reflects strong core profitability – before accounting distortions.
- It allows for effective comparisons across companies and sectors.
- A stable or growing margin signals efficient cost control and business scalability.
📘 EBIT Margin
📈 What is it?
The EBIT margin shows what percentage of revenue remains as operating profit after depreciation but before interest and taxes.
🧮 How is it calculated?
🏛️ Why is it important?
The EBIT margin reflects a company’s core profitability while accounting for capital intensity (e.g. machinery, infrastructure). It’s especially useful for comparing businesses with different levels of depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT margin shows that the company remains efficient even after factoring in depreciation.
- It’s especially relevant for capital-intensive industries.
- Stable or rising EBIT margins over time are a strong indicator of pricing power and business quality.
📘 Net Margin
📈 What is it?
Net margin shows how much of a company’s revenue remains as bottom-line profit after deducting all costs, interest, taxes, and depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
Net margin reflects a company’s overall efficiency – across operations, financing, and taxation. It shows how much actual profit is generated from each dollar of revenue.
🧮 Calculation
🎯 What does this mean for investors?
- A high net margin means the company is not only strong operationally but also manages financing and taxes efficiently.
- Peer comparisons reveal business quality and competitiveness.
- Declining margins despite revenue growth can be a red flag for rising costs or inefficiencies.
📘 Free Cash Flow Margin | ex SBC
📈 What is it?
The Free Cash Flow Margin shows how much free cash flow a company generates relative to its revenue. In simplified terms, free cash flow is calculated as operating cash flow minus capital expenditures. The Free Cash Flow Margin ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted metric.
🧮 How is it calculated?
Free Cash Flow Margin ex SBC = (Free Cash Flow − SBC) ÷ Revenue × 100
🏛️ Why is it important?
The Free Cash Flow Margin shows how efficiently a company converts its revenue into free cash flow. Strong free cash flow can provide financial flexibility for dividends, share buybacks, debt repayment, or further investments. The ex SBC version additionally accounts for the economic impact of stock-based compensation and therefore provides a more conservative view of cash generation from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A high Free Cash Flow Margin shows that a company converts a high proportion of its revenue into free cash flow.
- This can provide greater financial flexibility for dividends, share buybacks, debt repayment, or investments.
- The Free Cash Flow Margin ex SBC additionally accounts for potential shareholder dilution from stock-based compensation.
- The long-term trend is particularly important. Declining margins can, for example, result from higher investments, changes in working capital, or weaker operating performance.
📘 Earnings per share (EPS)
📈 What is it?
Earnings per Share (EPS) shows how much profit is attributable to a single share – and is one of the most important metrics for evaluating a company's performance.
🧮 How is it calculated?
The diluted share count reflects potential new shares that could be issued through options, convertible bonds, or other rights.
🏛️ Why is it important?
EPS is the basis for many key valuation metrics like P/E ratio, PEG ratio, or payout ratio. It enables comparisons of profitability across companies, regardless of their size.
🧮 Calculation
🎯 What does this mean for investors?
- EPS captures per-share profitability and is especially useful for comparisons over time or with analyst estimates.
- Rising EPS may signal consistent growth or share buybacks.
- Important: Always use diluted EPS for more realistic valuations – especially in companies with stock-based compensation.
📘 Free cash flow per share (FCF per share)
📈 What is it?
Free Cash Flow per Share shows how much free cash flow a company generates per outstanding share – after investments, but before dividends or debt repayments.
🧮 How is it calculated?
Free cash flow is calculated as operating cash flow minus capital expenditures (CapEx).
🏛️ Why is it important?
FCF per Share reveals how much real cash is available per share – useful for dividends, buybacks, or reducing debt. Unlike net income, free cash flow is harder to manipulate and often seen as a more reliable metric.
🧮 Calculation
🎯 What does this mean for investors?
- High FCF per share signals strong financial flexibility.
- It shows how much capital the company can effectively reinvest or return to shareholders.
- Particularly relevant for dividend payers and capital-efficient businesses.
📘 Short interest
📈 What is it?
Short interest indicates how many shares of a company are currently sold short – that is, borrowed and sold by investors who expect the price to decline.
🧮 How is it calculated?
It reflects the percentage of a company’s shares that are being shorted relative to the total shares available.
🏛️ Why is it important?
Short interest serves as a sentiment indicator: A high value may signal skepticism or bearish expectations – but also increases the potential for a short squeeze if prices rise unexpectedly.
🧮 Calculation
🎯 What does this mean for investors?
- Low short interest usually indicates market confidence in the company.
- High short interest can be a warning sign – or an opportunity if sentiment shifts.
- Especially relevant in volatile markets or ahead of key earnings releases.
📘 Employees
📈 What is it?
The employee count shows how many people a company employs worldwide – offering insights into its size, structure, and business model.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess operational scale, labor intensity, and cost structure. Combined with revenue and profit, it enables key metrics like revenue per employee or productivity.
🧮 Calculation
🎯 What does this mean for investors?
- A high headcount can signal operational complexity – but also significant growth capacity.
- Revenue per employee is a key indicator of efficiency.
- Especially useful for comparing tech, industrial, or service-heavy companies.
📘 Revenue per employee
📈 What is it?
Revenue per employee indicates how much revenue a company generates on average per employee – a key measure of efficiency and productivity.
🧮 How is it calculated?
The employee count is typically taken from the most recent annual report.
🏛️ Why is it important?
This metric helps compare business models – especially between labor-intensive and technology-driven companies. A high value suggests automation, operational efficiency, or strong value creation per head.
🧮 Calculation
🎯 What does this mean for investors?
- A high revenue per employee indicates a scalable and margin-strong business model.
- A low figure may reflect labor-intensive operations or lower value-add.
- Especially helpful when comparing tech companies to industrial or service sectors.
Septerna Stock Analysis
Analyst Opinions
16 Analysts have issued a Septerna forecast:
Analyst Opinions
16 Analysts have issued a Septerna forecast:
Septerna Events
Past Events
|
NOV
16
UBS Global Biopharma Conference 2026
3 days ago
|
|
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
|
StocksGuide Free
Septerna — UBS Global Biopharma Conference 2026
1. Question Answer
Good afternoon, everybody. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID biotech analysts at UBS. Happy to introduce the team from Septerna, Jeff Finer, CEO and Co-Founder; and Liz Bhatt, President and COO. Great to see you, Jeff and Liz. Thank you so much for joining us.
To start off, I'll hand it over to Jeff to go through some slides for a presentation for maybe 15 minutes, and then we'll have a Q&A after that.
Okay. Thanks, Alice, and thanks to the UBS team for inviting us. So for those of you who aren't familiar with Septerna, we're a company focused entirely on GPCRs or G protein-coupled receptors. At the founding of the company, we figured out a new way to do drug discovery for GPCRs. I don't have time today to tell you much about the platform, but I will make some forward-looking statements, so take that into consideration. But that platform has quickly evolved into a very interesting portfolio of products, and we'll spend time on a couple of these today.
So SEP-479 is our oral small molecule drug for hypoparathyroidism. It's focused on the parathyroid hormone receptor called PTH1R. It's currently in an ongoing Phase I trial. We anticipate that, that Phase I trial will read out in the first quarter of 2027. So we're excited about that data set, and we can spend some of the time today talking about what we hope to see in that data set.
Our second program, which is fairly newly announced is SEP-204. It's going after a target called TSHR for Graves' disease and thyroid eye disease. We presented just about 1.5 weeks ago data at the American Thyroid Association Conference, preclinical data. This is a compound that's moving along quite nicely on the way to starting in the clinic. It should be in the clinic in Q1 of 2027 as well. So it would be great to introduce you to that as well.
A couple of other programs that we may only touch on more briefly today. One focus is on mast cell target called MRGPRX2, where we have a compound SEP-631 that completed a Phase I trial in March, and we announced that data. We're excited about that compound. We think we've got a potential best-in-class profile for that compound. It is currently in between Phase I and Phase II as we are developing our clinical strategy around which indications to go after next.
And then the newest addition to our pipeline, the fourth program there is the second PTH receptor small molecule agonist program. This is for osteoporosis. And one thing that distinguishes the osteoporosis program from the hypoparathyroidism program is that for osteoporosis, you need to have a short-acting compound. There is something about bone biology and the interaction with the PTH receptor. We know from peptides that short-acting peptides are anabolic for bone. They cause bone formation, whereas for hypoparathyroidism, we actually want full day calcium control. So we want a long-acting compound there.
Beyond those, we actually have a few earlier-stage programs as well. We won't talk about those. But we also have a quite substantial partnership with Novo that we put in place about a little over a year ago now, middle of 2025. That collaboration is working on 5 targets, 4 concurrent programs. It's going quite well. Just last week, we announced in our quarterly earnings that Novo had selected the first development candidate from the collaboration and plans to move that forward.
Okay. So what I'd like to do with the time today is really spend it on 2 programs, the hypoparathyroidism program and the Graves' program. So SEP-479 came out of our platform, which we call the native complex platform, and we developed an oral small molecule that's actually quite potent. What we're looking at here is the PTH receptor in magenta. And you can see in green the PTH peptide. PTH peptide basically binds in the transmembrane domain and goes all the way up on the extracellular domain. This is a receptor that many companies have tried to find small molecules for, for literally decades and struck out. And we found not one binding pocket, but 2 distinct binding pockets for oral small molecules that allow those compounds to completely mimic what the peptides do.
In every preclinical model system that we've looked at, the small molecules for the PTH receptor, including SEP-479, do exactly what the PTH peptides do. We optimized that with our platform and led to this candidate. And so as I said, 479 is a potent oral small molecule. As I'll show you, it has some great activity in preclinical models. Just for the sake of time, we'll only focus on one of them today, one of the preclinical models, but it showed great activity in a rat surgical model of hypoparathyroidism. What I'll share today is some monkey PK/PD data. That is in a healthy monkey, and it's a good predictor of what we hope to see in our healthy patient trial that's ongoing. It's got great pharmaceutical properties. We projected that it would have a half-life between 40 and 80 hours, and we ended up at the long end of that. We've got a compound that now has a half-life of 3 to 4 days, which we think is actually quite important because it will allow us to actually achieve ideally very stable calcium control throughout the day. Well tolerated in GLP tox studies. And as I said, it's in Phase I trial right now.
So with regard to that monkey data, this is a 7-day study in healthy monkeys. And one thing that's important to realize is that healthy monkeys as well as healthy humans in our clinical trial generally have intact parathyroid glands, which is quite different than hypoparathyroidism patients who have frequently lost their parathyroid glands. In a healthy animal and a healthy human, the result of having those glands is that there's an endocrine feedback loop that tries to keep calcium stable. And with that endocrine feedback loop, what we expect to see when we dose our drug is endogenous PTH levels going down. And this is exactly what you're seeing here in the left graph. So this is endogenous PTH levels, and you can see it's a percentage change. We're lowering that by about 80% or so.
Here, once that is down and hits that threshold, you can see it kind of bottoms out there. We've got 4 different doses. As we dose up higher, we get increasing levels of calcium beyond that. So question is, what's the relevant amount of calcium increase that we hope to see? Well, the advantage that we have is that there have been peptides developed before us. And so YORVIPATH from Ascendis, which is the currently approved drug for injectable peptide for hypoparathyroidism. If we look at their starting dose and then retrospectively look at what it did in its Phase I healthy volunteer studies, it increased calcium about 0.5 milligrams per deciliter too, which was appropriate for a starting dose and then up to about 1 mg per deciliter at higher doses.
So moving on to our Phase I trial. This is a very standard single ascending dose, multiple ascending dose design, multiple cohorts. It's being run in Australia. We estimate about 150 subjects in this study. We're also planning to do a food-effect study as well. We're not expecting a food effect, but we want to work that out in the clinic to make sure that's the case.
So what we have disclosed a couple of months back is that 479 has a half-life of about 3 to 4 days. And again, this is something that will allow us to hopefully have very, very tight control with a once-daily dosing regimen. The multiple ascending dose portion of the trial was then extended to about 14 days. And the purpose of that was to try to achieve basically steady state levels. A good rule of thumb is that about 4 to 5 half-lives will get you to steady state. And we think in about 14 days, we should be getting close to that. As I mentioned, in terms of what we hope to see, we're hoping to see endogenous PTH levels go down about 50% and serum calcium to go up about 0.5 mg per deciliter to inform what would be a starting dose in hypoparathyroidism patients. As many of you know, hypoparathyroidism is a disease where the PTH replacement needs to be titrated on a patient-by-patient basis. So we want to be at that sort of starting dose and then be able to titrate a bit higher. So we are looking for levels up around 1 mg per deciliter at our high doses. Okay. And as I said, this trial should wrap up in the first quarter.
So just in the last few minutes, I want to introduce you to SEP-204, which is our new oral small molecule for Graves' disease and thyroid eye disease, which we announced just for the first time a couple of weeks ago. So we're looking at a different structure here. This is the TSH receptor. You can see that it undergoes a very large conformational change from an inactive state in blue to an active state in that more magenta color. So you can see a big conformational change on the extracellular domain. Inside the receptor, you can see a bit of a change there as well. And our goal was to come up with a compound that would prevent the binding of all autoantibodies. So Graves' disease and thyroid eye disease are diseases of autoantibodies that are directed to this TSH receptor and lead to all the hallmarks of Graves' disease, including hyperthyroidism as well as thyroid eye disease. So -- I'm sorry, SEP-204 basically binds in that region.
So here are some of the characteristics of the development candidates. It's a potent oral small molecule. One of the things that's actually quite important is that we have a selective compound. There are 2 very closely related receptors, FSH receptor and LH receptor. These are reproductive hormone receptors. And as Graves' disease is commonly found in women of reproductive years, we don't want to affect those reproductive hormone receptors. The compound has excellent pharmaceutical properties, and we project this one also to be a once-daily oral dose as well. And it has completed GLP toxicology studies and all we saw there was signs of exaggerated on-target pharmacology, including hypothyroidism. Phase I is on track here to begin in Q1 of 2027.
I'm going to share just a little bit of the data that we shared again at the American Thyroid Association meeting just about 1.5 weeks ago. So SEP-204 is, in this case, dosed to a rat, but it's dosed after dosing a Graves patient-derived antibody, which is called M22 that's shown in the diagram there. When M22 is dosed, you see in the upper graph, thyroid T4 hormone levels starting to go up. And then about 18 hours later, we start dosing SEP-204. For the animals that do not receive SEP-204, this is in the black curve at the top, you can see the thyroid hormone levels go up and then plateau. But we see 2 doses, 1 milligram and 3 milligram per kilogram, where you can see the thyroid T4 hormone levels basically normalizing. That little thin gray band that you see there is the normal hormone levels. So both of those land us in that normal range, which is exciting. We can also go up to a higher dose of 10 mg per kilogram. And there, we get more comprehensive suppression of the receptor and a decrease in thyroid hormone levels. The reason this is exciting to us is that it provides a suggestion that we may have dose optionality. We hope to work this out in the clinic where we may have some doses that allow us to normalize thyroid function and other doses where it allows us to fully suppress it.
Now moving on to a more chronic disease model. This is in a mouse. We've taken that same Graves' disease patient-derived antibody and dosed it over and over again for an 8-week period. What happens there is the animals get a phenotype consistent with Graves' disease, thyroid hormones go up, the thyroid gets enlarged. As you'll see, there's some significant changes in the thyroid histology and then the eyes begin to bulge as well. For the last 2 weeks of the study, we add on SEP-204, and you can see some reversal of that. So looking at the figures there, we see the thyroid histology and the thyroid size, the middle photo is the Graves' mouse. And you can see some significant disruption to the thyroid histology. That is now normalized when we treat with SEP-204, which is in the third image there. Thyroid size also starts to come down. The right side shows orbital proptosis. You can see the middle figure that is what a mouse with thyroid eye disease looks like, very proptotic eye compared to the left image, and then we're able to normalize that as well, start to reverse that. So we're excited about the prospects of this drug.
So just to kind of summarize some of the key features that I've already said, projected human half-life is about 20 to 40 hours. Again, we'll work that out in the clinic. And the preclinical safety studies were, again, all we saw were effects consistent with exaggerated on-target pharmacology, namely hypothyroidism.
One thing as we start to think ahead to patients is what do we expect to see in terms of biomarkers. I told you a story with PTH just a little while ago where we expect endogenous PTH to go down for the hypoparathyroidism study. For this, you can think about it very similarly. It involves another efficient endocrine feedback loop. And there, we expect TSH levels to go up, which is actually quite exciting. So hopefully, we'll see that in our Phase I study, which is again scheduled to begin around next year.
And with that, I'll just kind of wrap up and we can take some discussion, some questions.
Great. Thank you so much, Jeff. So starting with your 479 hypoparathyroidism program, I guess that's the most topical because the Phase I data is coming up relatively soon. It is in healthy volunteers, but it's kind of a proof-of-concept study, right, because of the way the mechanism works. So you described the reduction in parathyroid hormone and then the increase in serum calcium. Can you talk a little bit about what you really need to show and if we can compare that to existing therapy Phase I trials?
Yes. One important thing that everybody should know is that the biology, the fundamental biology of the receptor is the same in a healthy volunteer versus a patient. So both healthy individuals and patients have the same PTH receptor in the bone and the kidney. And what we've seen is that every compound that has worked in healthy volunteers has eventually worked in patients. So it is really kind of almost a proof-of-concept study there, even though it's not in patients yet.
With regard to comparison to the existing therapies, we consider YORVIPATH to be very much the gold standard here. It's a great drug. However, it needs daily injections. It has a projected -- it has a simulated half-life of about 2.5 days. And with our half-life of about 3 to 4 days, we think we're going to be in a similar range. So what we're hoping to see from our Phase I are doses that could be compatible with a starting dose in hypoparathyroidism patients. That would be endogenous PTH levels going down about 50% and serum calcium going up about 0.5 mg per deciliter. Again, that's just the starting dose for hypoparathyroidism patient. We'd like to be able to extend the range a little bit further than that. They showed that in their Phase I. So we're using them very much as a benchmark and hoping to see at the higher end of our spectrum, calcium ranges up to about 1 mg per deciliter.
Okay. So you just want to be in line with what they've showed basically.
Exactly.
And can you talk about YORVIPATH then and maybe the unmet need that's remaining in this indication. I think there's also about 70,000 patients in the U.S. So maybe talk about how those patients are currently served and the unmet need and the need for an oral therapy.
Yes. So there are about 70,000 to 80,000 patients within the United States. And basically, as Jeff had mentioned, these patients, the parathyroid glands have been removed, so they can't make PTH. So the ideal therapy for these patients is PTH replacement. Current standard of care is actually calcium and vitamin D. And so YORVIPATH is the first peptide replacement that's available. Again, as Jeff said, it's a daily injection. Right now, it's being primarily used for the more severe patients, patients who can't get under control with calcium or vitamin D, maybe at risk for ER visits as a result of it. There's a huge unmet need.
We believe that all patients should be on PTH replacement therapy, and we believe an oral small molecule really has the ability to expand the treatable patient population. Right now, the thought of going on a daily injection for the rest of your lives, again, these patients are diagnosed very early in their lives, so will be on treatment for decades. They really would like an oral alternative. And so certainly, patients who may be a little bit more moderate in nature are certainly asking for an oral alternative. But frankly, even those who are more severe right now on the injectables are looking to have an oral option, too, simply because, again, being treated for a long period of time -- for the rest of their lives and really hoping to get under control with the PTH replacement versus calcium.
Okay. So it sounds like the main patient population for an oral would be the milder patients, but then also potentially the more severe patients?
Really, the oral can be used across the entire spectrum. But we think right now, certainly, the more moderate patients, and some of them are just less interested in going on an injectable therapy, especially because it's daily, it's a little bit burdensome for them. And so that's why we believe an oral has the option to be able to expand it to more patients right now that might currently be open for an injectable therapy.
Okay. And can you talk about other -- actually before then, why is it so difficult to develop an oral small molecule for this receptor? Because it seems quite straightforward. Why wouldn't you want to have an oral for that.
Yes, it's easier said than done. So several big pharma companies have actually tried to do -- screen this receptor and find small molecules. It's just very difficult to find a small molecule that mimics a peptide. It's been kind of a historical challenge in the GPCR space and proved to be particularly difficult for this receptor. And as far as I know, we are the only company that's developed a small molecule that is effective on this receptor, good enough to hopefully show some data in a Phase I trial.
There's some more competition coming, I think. One, I think, is also an oral drug. So can you talk about where those therapies might end up being positioned and how you differentiate against the other oral?
So right now, we're the only oral PTH product that's out there. The other oral that's in development right now is a product called Encaleret, which has actually targeted the calcium sensing receptor. So a different mechanism of action. Its first path for development was for a special subpopulation called the ADH1 patients. And its mechanism is, one, as I said, through the calcium sensing receptor. So for that mechanism to work, you actually need intact parathyroid tissue to be able to produce PTH. Again, in the postsurgical patients, which is where we're focusing, a lot of patients have actually had those parathyroid glands removed or maybe there's only a portion that's remaining. And so mechanically, it's very different. It's done a very nice job in terms of balancing urine calcium. The Phase III that's underway right now actually measures a slightly different endpoint.
So the real key question here is, is it a suitable mechanism for postsurgical patients as well. We believe, again, a full PTH replacement really kind of going at the heart of what's missing within these patients, maybe a more direct approach, but we'll see what the Phase III data looks like with this other alternative. But again, since it's a different mechanism, we'll just have to see whether it's going to be able to stack up relative to PTH replacement or not.
And in terms of pricing, I know it's way too early to talk about pricing for your drug. But in general, in these kind of rare diseases, do the oral drugs have a lower price than the kind of injectable drugs? Or how does that usually...
Again, way too early to talk about that. It really focuses on really what the benefit is to the patient. And so again, as we continue to develop our drug, think about the benefits being provided for the patient. We'll be able to cross that barrier at that particular point in time.
Okay. And you mentioned titration. How will that play out if this succeeds in these patients?
Yes. So again, we can lean on the learnings of the injectable peptides. So typically, what would happen is a patient would start on a given dose. And those individuals are typically on calcium and vitamin D supplements. And so there is a titration protocol that we will need to develop in our Phase II trial, where we will dose up our drug, at the same time, we dose down the calcium and vitamin D supplements. So again, fortunately, there's been some precedent for how to do that with the injectable peptides. And we will probably start with a titration protocol much like that. It's something that goes over a number of weeks to get somebody into that right range. And one of the endpoints in some of these trials is freedom from excessive calcium supplements and vitamin D as well.
Okay. And then in terms of time lines for this program, should we expect similar trial designs and time lines as YORVIPATH given it's kind of a similar...
I think there's going to be some opportunities to go a little bit more quickly than they did. Just to kind of lay things out, if we finish our Phase I trial in Q1 of 2027, I think we hope to be in our Phase II trial by the second half of 2027. One of the things that we're hoping to do before starting that Phase II trial is to complete chronic toxicology studies. And we want those chronic toxicology studies done so that we can enroll patients from that Phase II trial into an open-label extension so that if they are benefiting from the drug, they can continue without having to go off of it.
Phase II programs are typically on the scale of dozens of patients. The goal of the Phase II program is to try to get to the right starting dose. We'll probably explore a couple of those as well as that right titration protocol.
Okay. Perhaps we can move to your thyroid eye disease, Graves' disease program. Earlier in development, you said you're going to be starting the Phase I in the next few months. What's the thought behind this as we think about the current treatment landscape? And same sort of question, what's the unmet need and why the need for an oral therapy?
Sure. So this program, again, is targeted to Graves' disease as well as thyroid eye disease. Again, thyroid eye disease is a major manifestation of Graves' disease, at least 40% of patients develop some symptomatology of thyroid eye disease. And so within Graves' disease, there hasn't been a lot of novel development for quite a long period of time, but there's still quite a bit of unmet need here. Within Graves' disease, patients are currently treated with antithyroid drugs. Many patients relapse, many patients don't hit remission. And as we know, as things progress into thyroid eye disease, very few options for more mild patients and some options for the more moderate to severe. So each of these different patients within the spectrum have ongoing unmet need here.
TSHR, one of the really exciting things about this is, this is the receptor where the autoantibodies are actually generated. So it really is relevant for both disease states. And so as we think about our own development plans, we'll think about kind of how best to be able to address all of these different patient populations.
Okay. And can you provide some more detail on what the Phase I study could look like and what you hope to see and when that data could be shared?
Sure. So like I said, it's a disease with a very efficient endocrine feedback loop. So we're going to start in healthy volunteers. It will be a standard sort of single ascending dose, multiple ascending dose design. What we hope to see there is endogenous TSH now going up. And then if we get up to high enough dose levels, see the thyroid hormone starting to come down. So that's what we'll be looking for initially. One of the things we'd like to do shortly thereafter is get into some Graves' disease patients and demonstrate that we can see the same thing.
Okay.
And with regard to timing, if we get that trial started in the first quarter, the hope would be to have that healthy volunteer data before the end of 2027.
Great. Maybe in the last few minutes, we could touch on your X2 program quickly. Where are you at with this? I know there was some hope for more traditional kind of mast cell-driven diseases, chronic spontaneous urticaria and those unfortunately failed. You've got some other competitors which have programs and one of them has decided to go into migraine. So curious how you're thinking about these indications and whether migraine could be a potential indication for you to explore?
Yes. So one of the really exciting things about X2 and mast cell diseases is there is a variety of different diseases where mast cell activation seems to be implicated. As you had mentioned, the original strategy was to focus on a large CSU study. Jeff can talk a little bit about our product profile and our excitement around 631 really being one of the best molecules out there. But certainly, relative to that data, we want to take a step back and think about some other approaches. We've decided to take an approach, which is more focused on smaller studies that are more signal finding to really identify indications where X2 can play a critical role here.
And so specifically as it relates to migraine, there's a wealth of data that's emerging, certainly as it relates to mast cells really being important relative to migraine and X2 being present, not to mention the fact that several of the neuropeptides like PACAP are also agonists for the X2 receptor. So there's a lot of wealth of evidence coming together why migraine might be a very relevant indication here. Rather than jumping into a large Phase II study, what we're trying to identify is what can be a smaller signal finding study, whether it be a challenge study or another design in nature to be able to really see if there's a signal here relative to migraine and then we would jump into a larger Phase II. So as we think about the other host of indications, things like interstitial cystitis or asthma as well, we're really trying to think about what might those study designs be to see whether we can get a signal. But Jeff, maybe you could speak to a little bit about the profile.
Yes, I can share a little bit about the profile. We think we've got a very, very good molecule here. We've got a unique mechanism called the negative allosteric modulator, which is a situation where we bind outside of this very promiscuous binding pocket on the receptor. The receptor, just for those of you who haven't thought about it much, has literally dozens of endogenous ligands that bind to it. And our profile was to come up with a compound that would prevent the activation of the receptor by all agonists of this. And we came up with a very unique mechanism, which is that the compound, when it binds into the transmembrane domain of the receptor, results in a conformational change that closes the binding pocket off completely so that none of the endogenous agonists can bind it. And our compound has a very, very slow off rate. It's on there for hours when the compound is on there. So we think it's also important to have a nearly complete inhibition of the receptor. So going all the way up to probably 99% receptor occupancy, we think it is going to be important because mast cells are kind of primed to degranulate if a little bit of activation sneaks through. So the goal is to have a great compound. We've got that great compound, very safe in the Phase I trial, once daily pill and we think it's got an opportunity across a whole bunch of indications.
Great. I think that's all we have time for. But thank you, Jeff. Thank you, Liz. Thank you, everyone, for joining.
Septerna — Bank of America Global Healthcare Conference 2026
1. Question Answer
The end of our first day of our Annual Healthcare Conference in a very toasty Las Vegas. I'm very pleased to have join us right now, Jeff Finer of Septerna, who will be providing us with the presentation. Jeff?
Okay. Yes. Thanks, Jason. Thanks for the invitation to present with you guys here. It's good to see a few people still in the room late in the day. I'm going to tell you about Septerna. For those of you who don't know us, we're a company focused entirely on GPCRs or G protein-coupled receptors, and we found a new way to do drug discovery for them. The presentation will include some forward-looking statements.
But just a kind of quick overview of the company. We've got a platform that we call the Native Complex Platform that's allowed us to do drug discovery for GPCRs in a new way. It's allowed us to tackle previously difficult to drug GPCRs. And part of our portfolio strategy in general has been to go after well-validated targets with early clinical readouts. Every one of our programs, the ones we'll talk about today, has a meaningful Phase I readout that is important. We're well capitalized. We announced financial results just from the Q1 last yesterday, and we've got a cash runway into 2029.
A couple of lead programs that we'll talk about today. We'll spend nearly the entire time talking about 2 of the programs. One is SEP-479, which is our parathyroid hormone receptor agonist for hypoparathyroidism. This is one that we recently announced the start of the Phase I trial, announced that start just a few weeks back.
The second program, SEP-631, is going after a mast cell target called MRGPRX2. That one we announced very promising Phase I data just 2 months back, just in March, and I'll share that data with you today.
And then I'll briefly introduce you to our thyroid stimulating hormone receptor program as well. This one is going after Graves' disease. And finally, last but not least, we have an incretin receptor agonist set of programs that we end up partnering with Novo. We announced a big deal with Novo last year, and that collaboration is off to the races.
Okay. So jumping into our SEP-479 program. For those of you who don't think about hypoparathyroidism all the time, it's important to understand a little bit about parathyroid hormone physiology. So PTH is the master regulator of blood calcium levels. It's secreted by the parathyroid glands, and it has its effects on a receptor called PTH1R in the bone and the kidney. Those effects on the bone and kidney lead to increases in serum calcium, either through mobilization of calcium from bone, resorption of calcium on the kidney, and there's also effects on the GI tract as well.
Patients with hypoparathyroidism have generally lost these parathyroid glands and an inability to regulate their blood calcium. So they end up with hypocalcemia and a whole bunch of consequences of that, including side effects.
SEP-479 is our clinical candidate. We'll spend some time talking about today. It's a very potent selective oral small molecule. In this space, there's been a lot of peptide therapeutics, but this is, to our knowledge, the first effective oral small molecule. This is our second-generation compound, we have an earlier one that ran into an unexpected safety finding. But SEP-479 is our second-generation compound.
This compound has shown activity that's very comparable to PTH peptides by all measures, cell-based assays, animal models. We've shown efficacy in a rat surgical model of hypoparathyroidism. I don't have time to share that with you today. But I will share with you a very interesting monkey PK/PD study, which we think is a good simulator of what a healthy volunteer study should look like. Compound has excellent pharmaceutical properties that we think project a once-daily dosing. And as I mentioned, the Phase I trial was just recently kicked off.
Okay. So this is the monkey PK/PD study that I was alluding to. One thing to know about this physiology is that healthy volunteers are very different than hypoparathyroidism patients. And healthy monkeys are -- have the same situation as a healthy volunteer and that they have intact parathyroid glands. Those parathyroid glands, because the endocrine feedback system is so efficient, they can dial up and dial down PTH release from those glands very efficiently in response to any moves in serum calcium to try to hold serum calcium levels as tight as possible.
And so what we do expect to see in a healthy volunteer as well as in a healthy monkey, the first consequence is the endogenous PTH secretion will go down. And what we're looking at here is a 7-day study with once-daily dosing followed by a 5-day recovery period. And what you can see on the left graph is that after just a single dose, the endogenous PTH levels are down about 80% or so. Once you've bottomed out PTH levels, your ability to turn down PTH, you start to get serum calcium increases in healthy volunteers as well.
And we've learned some lessons from the PTH peptides that have been before us in clinical development, including that Novo pass from Ascendis, which is that if you look back retrospectively at the doses that work in healthy -- I'm sorry, in hypoparathyroidism patients and then see what those same doses would have done in healthy volunteers, you get a target range of calcium that you'd like to see increase in the healthy volunteer to predict a starting dose in hypoparathyroidism patients. And that amount of calcium increase is probably on about the scale of about 0.3 milligrams to 0.5 milligrams per deciliter. And so we're seeing that in this monkey study, which is promising.
The rest of the preclinical development for this compound went very, very smoothly. As I mentioned, it's a potent oral small molecule. PK studies, we did across multiple species mice, rats, dogs and monkeys. And it led to a projected human half-life in the range of about 40 to 80 hours, which, again, we think is -- should be compatible with once-daily human dosing. We think anything above 20 hours would be good for once-daily dosing.
And then on the safety side, we did 3 GLP tox studies rats, dogs and cynos for this particular compound. And all we saw was on-target effects, on-target effects of hypercalcemia, no other significant side effects. So we were excited about this, decided to move it into the Phase I trial.
Here's a quick overview of this Phase I trial design. We're doing a randomized placebo-controlled single ascending dose and multiple ascending dose study. We're doing a food effect study as well. The number of cohorts is a variable here. We're doing -- we're going to dose escalate. We're going to be looking primarily at a few things. Safety and tolerability, obviously, always comes with Phase I trial as does PK. But we're going to be looking at those markers that I just mentioned in that monkey study, endogenous PTH going down and calcium going up.
In terms of the translation to human trials, I mentioned this already. Based on the peptide experience, we sort of know what we want to look for. And the objectives of this study are to figure out ultimately what that starting dose should be in hypoparathyroidism patients. With that, we anticipate results from this study either late this year or early next year, again, it depends on the number of cohorts that we end up doing.
Okay. So quickly moving on to our second program. This is SEP-631, going after a mast cell target called MRGPRX2, I'll call it X2 for short. Mast cells increasingly important targets of a number of diseases, a number of drugs at this point in time. Mast cells live in proximity to 2 important systems in tissues. One are sensory neurons, where they control pain and itch. And then also they're near tissue capillaries and mast cell degranulation can lead to release of immune cells from those blood vessels as well as edema. And these lead to positive feedback loops of activation.
So a little bit on SEP-631. This is a very potent compound. It has a mechanism that we call a negative allosteric modulator. And negative allosteric modulator is something that binds outside of the exogenous binding site of the exogenous ligands and turns off the receptor. And we've got an insurmountable one here. We released some recent data on the potency. So we've got a very potent compound, high binding affinity, Ki in the 500 picomolar range, a very slow off rate when the compound is on the target. It turns the target. It's on the target for hours. And importantly, we've been able to show that we're able to lock the receptor in a very inactive state.
So what we're looking at here is the receptor. From the extracellular view, you can see the very large binding pocket in teal. We've colored one of the extra loops in magenta, so we can just follow it. If you look at the transmembrane view, you can see that there's an endogenous ligand that fits in there, that's cortistatin-14. When 631 binds to X2, a very remarkable thing happens, which is the extracellular loop pulled over and basically completely block the binding pocket. So this is a unique mechanism where if you take this ability to turn off the receptor combined with a very slow off rate, we're pretty much turning the receptor off.
That showed good effects in animal studies led to this Phase I study. Phase I was a single ascending dose, multiple ascending dose study plus a food effect. But importantly, in the multiple ascending dose portion of the trial, we did a skin challenge test and we think is actually quite relevant to this condition.
Importantly, on the safety side, safety of this compound was very well tolerated, pretty much indistinguishable from placebo, which was great. PK properties were also very promising. It's got a 24-hour half-life, which we think will sustain once daily dosing. And then there was no food effect. So we should have an oral pill that could be taken any time of the day, which would be great from a convenience standpoint.
The data we're particularly excited about is the icatibant skin challenge data. So I'll spend a moment telling you about that. Icatibant is a drug that's dosed subcutaneously. It's got an off-target effect on this receptor that leads to mast cell degranulation and a skin reaction. We did 2 doses of icatibant, 10 microgram per ml and 100 microgram per ml as well as a negative control, which is saline and a positive control, which is histamine.
And what we wanted to see, if you inject anything into your skin, you get a skin reaction even if it's just saline. We wanted to see how much we could dampen down the response from icatibant to the saline level. And this was the data that we shared at the AAAAI meeting a couple of months back, which showed that at the low dose of icatibant, we're able to take this response all the way down to saline even with our lowest dose tested, which was 10 milligrams once a day, which is quite exciting.
And at the high dose of icatibant, which represents a higher bar, we saw a nice dose -- a dose-dependent squelching of the icatibant skin response all the way down to baseline as well at the highest doses. So we're excited about what we saw here. We think we've got an effective compound, and this data shows that we're effective in humans in the skin.
So where are we going with this compound? There are a ton of mast cell indications. Seemingly every day, there's new publication with roles of mast cells in different disease stage. There's many. There's many -- most common place that everybody goes with this target and mast cells first is chronic spontaneous urticaria. We're thinking along the same lines of doing that as well. So we're planning to do a Phase II study in chronic spontaneous urticaria. We're planning to do a chronic inducible urticaria study along the way with that as well.
And we're also exploring a whole variety of other indications, many of which are listed there on the right-hand slide -- right-hand part of the slide, including atopic dermatitis, interstitial cystitis, migraine and asthma as well. So we're thinking about cost-effective ways to do signal finding studies in other trials.
Just really briefly, with regard to our TSH receptor program, this is one that we're going after Graves' disease. Graves' disease is becoming a hotter area of investigation these days. One thing that makes Graves' disease quite challenging is that every patient develops their own autoantibodies that activate this TSH receptor in both the thyroid gland as well as in the orbital fibroblast behind the eyes. That's what leads to both thyroid eye disease and the Graves' phenotype.
And again, one challenge is every patient has their own antibodies and they're polyclonal in many cases. So we need an approach to basically turn off all the antibodies if we can. And again, once again, we're using a negative allosteric modulator in this particular case as well. In terms of the status of this program, we believe we've got line of sight to a development candidate and hope to have more to say about that later in the year.
And with that, I will just kind of quickly wrap up with a snapshot of the pipeline. Things that we're looking for later this year are the Phase I data for SEP-479 in the PTH program, either late this year or early next year and for SEP-631 getting into Phase II later this year. So I'll stop there and we probably have time for a question or 2.
Questions from the audience?
I guess when you take a step back and you think of the platform itself, I mean, obviously, G-coupled protein receptors have been a focus for many drug developers. I guess what gives you sort of conviction that kind of the approach here is going to prove much more, I guess, fruitful, especially just given worries about off-target effects?
Yes. It's a great question. Maybe I'll just kind of quickly say just a little bit about our platform and a little bit what's different about it. So I've got a slide here that shows this. With this native complex platform, we found a way to actually get these receptors outside of cells. That's very important. Nobody had actually ever done that before and kept them functional. They cross the cell membrane 7 times. They will quickly denature if you take them out.
So we found a way to reconstitute them with all of their natural binding partners, including the G proteins, ligands, all in an artificial lipid bilayer. This has allowed us to do structural biology at an unprecedented pace. We've solved more than 150 high-resolution structures for each of our programs to date with this platform. We found novel binding pockets that the world didn't know about. Many times, they've been cryptic inducible pockets as well.
We've also got technologies to allow us to screen millions of compounds and use the combination of technologies to optimize quite quickly. So we think we've got a competitive advantage at the early part of drug discovery to find novel binding pockets. And we've got the evidence. Finding small molecule agonists for peptide GPCRs has been a big breakthrough for us and also finding allosteric modulators is something that the whole world struggle with.
Dr. Finer, thank you so much.
Okay. Thanks.
Financial data from Septerna
Revenue
Revenue is the sum of all sales generated by a company, e.g. for its products or services.
Revenue (TTM) metric explainedDirect Costs
Direct costs are the costs incurred directly in connection with the manufacture of the product or service.
Gross Profit
Gross Profit indicates how much of the revenue remains in the company after deducting direct production costs. If the percentage share of sales is calculated, this is referred to as the gross margin.
Gross Profit metric explainedSelling and Administrative Expenses
Selling, general and administrative expenses (SG&A) include all expenses for marketing and sales as well as the general administration of the company.
Research and Development Expense
Research and development costs (R&D) provide information on how much the company invests in the research and development of its products. The costs are particularly interesting as a percentage of revenue and in comparison to direct competitors.
EBITDA
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the company's earnings before interest, taxes, depreciation and amortization. The EBITDA margin is calculated as a percentage of sales.
Depreciation and Amortization
Depreciation represents reductions in the value of the company's assets (e.g. due to wear and tear on machinery).
EBIT (Operating Income)
EBIT (Earnings Before Interest and Taxes) is the company's profit before interest and taxes, also known as the operating income. The EBIT Margin is calculated as a percentage of sales at
.
Net Profit
Net Profit represents the profit or loss after deduction of all costs.
Net Profit metric explainedStocksGuide Premium
| Jun '26 |
+/-
%
|
||
| Revenue | 99 99 |
13,445%
13,445%
100%
|
|
| - Direct Costs | - - |
-
-
|
|
| Gross Profit | - - |
-
-
|
|
| - Selling and Administrative Expenses | 34 34 |
41%
41%
35%
|
|
| - Research and Development Expense | 121 121 |
54%
54%
122%
|
|
| EBITDA | -42 -42 |
58%
58%
-42%
|
|
| - Depreciation and Amortization | 1.65 1.65 |
6%
6%
2%
|
|
| EBIT (Operating Income) EBIT | -44 -44 |
57%
57%
-44%
|
|
| Net Profit | -24 -24 |
72%
72%
-25%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Septerna directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Septerna Stock News
Company Profile
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
StocksGuide Premium
| Head office | United States |
| CEO | Dr. Finer |
| Employees | 130 |
| Website | www.septerna.com |


